08/14/2026
This Q2 healthcare earnings season told a completely different story depending on where you sat inside it.
Eli Lilly posted 48% revenue growth. Novo Nordisk reported a decline driven entirely by a one-time accounting comparison. Stryker delivered 9% organic growth after recovering from a cyberattack. Boston Scientific beat Q2 estimates and lowered Q3 guidance in the same press release. Bristol Myers Squibb grew EPS by 40% while the legacy portfolio declined.
Same industry. Same earnings season. Completely different financial pictures.
The Lilly rep sitting on concentrated gains near all time highs has a different conversation than the BSX rep whose shares vested near $100 and are now worth less than half that. The Intuitive Surgical rep whose RSUs vested above $500 is in a different position than the AbbVie rep watching the Apogee acquisition close this quarter.
Every one of those situations requires a different conversation. There is no template for this.
The income and equity that healthcare sales professionals build in this industry does not move in a straight line. The reps who build financial plans around the reality of that environment are in a different position than the ones who assume the current moment is permanent.